This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
The Myeloma Trial Finder is intended only to provide information about clinical trials currently available in the UK. Trials included on Myeloma Trial Finder are not necessarily endorsed by Myeloma UK. Clinical trials involve inherent risks and any decision to participate, or not participate, in a clinical trial should be taken only after a careful assessment of the risks involved in it. Please speak to your haematologist if you are interested in taking part in a clinical trial. To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder
There are currently 25 open trials.
In 117 locations
What is a Clinical Trial?
There are currently 25 open trials
- Oxford pre-cancerous disorders study (OxPLoreD)
- A study evaluating S65487 for the treatment of relapsed/refractory myeloma patients
- bb2121 CART-Cells in relapsed/refractory and high-risk myeloma (KarMMa-2)
- Using diffusion weighted MRI to measure myeloma disease burden and bone loss (LOOMIS)
- Daratumumab in combination with standard myeloma treatment
- Exercise in transplant eligible myeloma patients (PERCEPT)
- Daratumumab with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients
- Venetoclax and dexamethasone in patients with relapsed or refractory multiple myeloma (CANOVA)
- Daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) in newly diagnosed AL amyloidosis
- Trial of immunomodulatory therapy in high risk solitary bone plasmacytoma (IDRIS)
- Effects of an exercise programme on smouldering myeloma and MGUS
- Selinexor with cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma patients (MUK twelve)
- Tanezumab for bone pain in myeloma
- Donor lymphocyte infusion after stem cell transplant in myeloma (ProT4).
- CC-92480 in combination with dexamethasone in relapsed and refractory multiple myeloma
- AZD4573 in relapsed or refractory myeloma
- Ixazomib, pomalidomide and dexamethasone for relapsed and/or refractory myeloma patients
- Observational evaluation of myeloma patients (PREAMBLE)
- Image guided theranostics in myeloma (iTIMM)
- MUK nine b: OPTIMUM
- CAR-T cell therapy for relapsed and/or refractory myeloma (APRIL)
- Melflufen and dexamethasone in myleoma patients refractory to lenalidomide (OCEAN trial)
- CC-220 monotherapy and combination for relapsed and refractory myeloma patients
- Myeloma XII (ACCoRd)
- GSK525762 trial
Trial Title:
Oxford pre-cancerous disorders study (OxPLoreD)
Treatments:
Observation
Myeloma stage:
Smouldering, MGUS
Trial phase:
Summary:
This study aims to uncover new biological markers which help identify patients who are more likely to develop myeloma by observing and monitoring patients with non-cancerous disorders, MGUS (monoclonal gammopathies of undetermined significance), Waldenstroms Macroglobulinaemia (WM) and Smouldering Myeloma (SM).
Locations:
Churchill Hospital, Oxford
Who can enter the study?:
Patients with IgM, IgA or IgG MGUS, smouldering myeloma or non-symptomatic Waldenstrom’s Macroglobulinaemia who have been diagnosed in the last two years.
What's involved?:
Patients will be studied for up to 5 years.
Patients will be required to:
- Provide blood, bone marrow and saliva samples at key time-points.
- Answer questions or complete questionnaires about what it is like to live with one of these conditions
Clinical Information
(for Medical Professionals):
This observational study to identify clinical, genomic and immunological predictive markers of progression to malignant disease. The study is open to patients diagnosed in the last 2 years with early-stage Chronic Lymphocytic Leukaemia (CLL), Monoclonal B-cell Lymphocytosis (MBL), Monoclonal Gammopathy of Uncertain Significance (MGUS), asymptomatic Waldenstroms Macroglobulinaemia (WM) and Smouldering Myeloma (SM). For more information, click here.
Find out more about Myeloma UK:
Visit www.myeloma.org.uk